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INTRODUCTION 
In recent years, fungus infedtions have become of 
increasing interest either as the sole cause of disease 
in man or as a complication of certain pre-existing 
conditions. Human infection with fungi of the class 
Phycomycetes (mucormycosis) fall mainly if not entirely 
into the latter category. At the present time, there are 
few if any unequivocal cases in which these organisms have 
appeared as pathogens of man without the presence of 
some predisposing factor such as severe diabetic 
acidosis, cancer (especially leukemia), or long term 
drug therapy with antibiotics, steroids, or antimetabolites. 
The importance of infection with Phycomycetes is becoming 
more evident as indicated by the increasing number of 
articles in the literature referring to the pathogenicity 
of these organisms. In man, these fungi almost always 
produce a rapidly fatal disease. In most of the cases 
reported, the diagnosis of fungus infection was either 
not suspected at all or discovered only when the disease 
had progressed to a far advanced state. As indicated 
above, there are a fairly limited number of circumstances 
in which one sees this disease in its serious form. In 
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the physician of the factors involved in the ~redis-
position to this disease could have either resulted 
in its prevention or, at least, an early diagnosis 
1d th chance of cure. Consec~uently, considers,ble c:pc:tce 
in this revie11 of mucormycosis is devoted to this aspect 
of the disease. 
HISTORY 
14 . Bake 2s usually ziven credit for the report of 
the first authentic case of human infection by a 
Phycomycete. In 1869, he described a case of otitis 
externa ce,used by the organism, :Mucor mucedo (class 
Phycomycetes, order mucorales). The earliest acceptible 
case of a Phycomycete involving the lune; ~ .. :s,s 13i ven by 
32 50 Furbringer in Germ,:my in 1876. Lichtheim' s experi-
ments in rabbits on the pathogenicity of mucorales 
(Mucor cormymbfer and Mucor rhizonosidormis) in 1884 
gcwe further evidence of the potential harmful effects 
69 
of these orgs_nisms. The follm·Tine; yeG,r, Pe,lteuf 
reported the first case of a disseminated infection 
from a Phycomycete. It was established that the 
infection ,;,·2,s due to a fungus belonsins to the order 
Mucorales and, as R result, he named the diseaee 
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"mycosis mucorina" or mucormycosis. 
Mucormycosis has only recently been recognized 
as a serious disease in the United States. The first 
unequivocal American casesof cerebral and pulmonary 
mucormycosis did not appear in the literature until 
36 3 
1943 . and 1948 respectively. Since then, at least 
twenty more cases of both pulmonary and cerebral 
involvement have been reported in the United States. 
Moreover, as will be considered later in this paper, the 
disease is frequently not recognized antemortem or 
postmortem and, hence, it may be much more common 
than is now appreciated. 
MYCOLOGY 
The Eumycetes (true fungi) are separated into 
two classes, those having septate mycelia and those 
characterized by lack of septation (coenocytic). The 
Phycomycetes belong in the latter class. In this 
class only three families have been observed as 
pathogens of man, namely Mucoraceae, Mortierellacea~ 
and Entomophthoraceae. Only the family Entomophthor-
aceae is not considered to belong in the order Mucorales. 
It is customarily felt that the term "mucormycosis" 
should be applied only to infections caused by members 
11 
of the order mucorales. Conse(uently, if one used 
this restricted definition, it is a?parsnt that a specific 
disease entity v.rould have to be created for the rr-re 
cases of fungus infection due to members of the 
Entomophtoraceae. In this family only one species, 
Basidiobolus ran2rum, has been found to be able to 
cause disease in man and it has been seen only in two 
28 51 patients. ' Furthermore, nevv clinical n2"mes VJould 
have to be established if other f milies of Phycomycetes 
not 1'.'1 thin the order Mucorales vrere found to be pathogens 
in man. Since this could create undue confusion, it 
has been proposed recently that the term "phycomycosis" 
be used instead of mucormycosis to desicnate a fungus 
infection caused by any member of the Phycomycetes.52 
Hm-:-ever, I feel the tHo exceptions are not adec:uate 
reason to coin a ne1·r term •.-rhich, at the !;reseC"lt time, 
seE:ms to have too broad connoto.tions. If there occur in 
the future as ap11reciable increase in the nurrber of infections 
due to Phycomycetes not l:ti thin the Mucorales but vri th a 
pathological and clinical picture closely simil2.r to 
that seen in this order, it would then seem justified 
to abandon the term mucormycosis. 
Two species of the family Mortierellaceae have 
been reported as pathogens in man. 43 These are 
Mortierella mycetomi and Morti~rella ni~eo. 
Mucoraceae (bread molds) is by f~.r the mcst im-
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port:::mt family in the production of mucormycosis; it 
includes such genera as Mucor, Absida, and Rhizopus. 
In tissue section, it is stated commonly that the 
order of a Phycomycete can be determined on the basis 
f i . 54 o a t~:P cal m~croscopic appearance. Hm-;ever, some 
authors feel that it is impossible to differentiate the 
various orcters of this class under these condit:~ons 
>Jhereas others consider the characteristics of the 
funsus to be :=ufficiently distinctive th2t even the 
f:;.mily cc:m be determined ui th :-·ccurncy. In the usual 
description siven for members of t:1e !'1ucor<>.les in tissue 
section, it is stated that the hyphae ure broad in 
di<\meter ( 4 to 12 microns) and nonse~Jtc:tte •::i th brc:mchinc 
8 
at richt ancles reachinG a lensth of up to 200 microns. 
Everyone o.grees that further identifico.tion :::.s to cenus 
and species cc.n be mo.de only by culture since charo..cteristic 
sporulQtion is usually not present in tissue. Differ-
entiation by culture of the various s~ecies ~ithin the 
genus is determined by typical variations in their 
i . d 17 s . sporang o., s};orang~os:_::)ores e.n _ zycos::;ores. porane;~a 
occasionally may be produced in walls of bronchi40 
where oxysen is abundant; on the contrary, in other 
tissues, the organisms are seen only as nonre~tate ~ycelia. 
All the mucoraceae sro,·: rapidly a.nd ~.bundc.ntl;y in 
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ordino.ry culture media. However, this is not t~·uo 
· .. ·i ~h respect to a.ll the members of the order Mucorales. 
For exampl0, the genus Pilobus (order Mucorales, family 
Pilobaceae) seems to be able to grovl only upon dung 
41 
agar. Odd ermrth requirements me.y be the reason vrhy 
other Phycomycetes have not been found as pathogens in 
man. Members of the Mucoraceae may be isolated from 
almost c:.nyv:here in the environment. They exist largely 
HS saprophytes in soil and on msJ1U:':"'e, frili ts, vegetables1 
35 
and starchy food such as bread. Infection in birds, 
dogs, pigs, horses, ?2 68 55 r:md cm·rs h.·l.Ve been re~>ortect.- ' ' 
The fungus has been cultured from the nose, sc.st::.--ointestinal 
tract, and skin of he~lthy individuo.ls. 16 The sites of 
loce?.lization in the body -.. ,-here t~e ors2nism may be found 
v1hen it acts as a p.e.thoe;en 1'lill· be discussed· below 
under the v~.ious clinical forms of the disease. 
PATHOLOGY 
Since the l1ucorales are ubiquitous in nature, it 
is essential to find histolosico..l evidence of the 
typical hyphae in tissue before the diasnosis can be 
macle of e.ctual infection by these o2.··s::::.nisms. In tissue 
the hyphae stain i·.:ell with heme.toxylin ,"'.nd eosin and 
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. even better 1·:i th iron hematoxylin alone. 8_ The hyphae 
exhibit a marked affinity for arteries. They inV2-de 
the ':rall breaking out in some sections through the 
adventitia e.nd in othe:~s through the in time.. A similar 
situation occurs some1;hat later in the veins. In both 
cases, this results in the formation of thrombi 1·rhich 
can subsequently lead to emboli. In the thrombus, 
along '.·.'i th its usual constituents, the organisms c2-n 
be seen. In addition, the hyphae are often of 
sufficient size in themselves to occlude small blood 
vessels or capillaries. As a result, infarction 
leading to necrosis of tissue in various ~J,s.rts of the 
body is the principal pathological findinc of the disease. 
The inflammc,tory reaction to isols-ted or clusters. of 
11 hyphe,e is reported as slight. Their ~;resence in 
muscle and fat tiseue seems to evoke l;racticc"lly no 
78 
response eut 2-11. Although intense infl':.n:r;;~,tory reaction 
is seen occasionally with marked infiltr~tion of poly-
r::4 
morphonuclear neutrophilic leu.1wcytes, ::> it a~Yoears 
11 
to occur only in tis2,ue injured by vc-scul-::r obstruction. 
11 
The follm·Ting picture taken from Bauer et o_l. illustrates 
the typical pathological finding seen on tissue 
examin8,tion. 
• 
n 
- o -
.CTaken from Bauer et a111 p . 824 )' 
' 
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Organisms also invade lymphatics and nervous tissue. 
The latter is quite resistant to infection and it is 
often the last tissue to be inv.olved even when all 
78 the other tissues in a given area are invaded. 
CLINICAL FORMS 
Mucormycosis differs from most other mycot1cilc 
infections in that it is an acute rather than a 
chronic infection~ It may be divided into two broad 
subdivisions of types of infection, superficial and 
visceral. 
SUPERFICIAL MUCORMYCOSIS 
This group includes involvement of the skin, 
fingernails, and external ear. 
Mucormycosis of the skin is an extremely uncommon 
entity. In fact there is only one well documented 
case in which definite histologic evidence of 
46 involvement was seen. The patient {age 26) was 
a moderately severe diabetic.who presented with an 
ulcer of the leg covered by a black eschar. After 4 
months of treatment with oral potassium iodide and 
control of the diabetes, the ulcer healed. 
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Paronchyia84 and a case of involvement of face 86 
with Mucoraceae have been reported. However, in these 
instances the diagnoses were made only by culture 
which does not necessarily implicate the funeus as 
the causative agent since members of this family can 
be found on the skin of everyone. 
VISCERAL MUCORMYCOSIS 
The visceral types of infection can be separated 
into 4 main groups: (1) pulmonary (pulmonary mucor-
mycosis), .( 2) gastrointestinal,· ( 3) involvement of 
head and neck structures and (4) disseminated. The 
following chart is taken from a fairly comprehensive 
43 
recent review of mucormycosis by Hutter. 
OR~AN LOCAJ,.JZA'fiC>N OF MUCORMtCOSlS 
IN CASES .\REPORTED BEFORE ANn ?.:; . 
· AFTER 1900 <).r, ·, 
Total 
no. 
cases 
Cases repor~ before JPJO 
Lung 15 
Ear, external canal 9 
Brain 2 
Pharynx 2 
Skin 2 
Stomach 2 
Tongue 2 
Palate I 
Small intestine I 
Cases reported afta 19UO 
Lung 32 
Brain 22 
Eye, orbit 15 
Skin I~ 
Stomach 13 
Kidney II 
Carotid artery 6 
Paranasal sinuses 6 
Small intestine .'i 
Spleen .:; 
Esophagus 4 
Heart 4 
Cavernous sinus 3 
Colon· J 
l'\osc ,l 
Palate 3 
Larynx 2 
Liver 2 
Diaphragm 2 
:!\farrow I 
• Pancreas I 1· Pituitary I 
I Spinal rord I Thyroid I "Visceral" I 
No. 
quest. 
cases 
9 
... 
1 
2 
0 
6 
I 
1 
... 
1 
·Sif •. 
orcan. inv., 
no;~ 
13 
9 
... 
I 
2 
2 
2 
I 
19 
·6 
2 
10 
9 
. .. 
1 
2 
... 
I 
11?) 
43 (Taken from Hutter 
p.332) 
It depicts nicely the relative frequency which the 
fungus has been identified in various parts of the body. 
However, this chart does not include any of the recently 
reported cases in 1959 and 1960 as well as a few before 
this period. In order to bring the subject up to date, 
the following cases with their . sites of organ localization 
should be added to this table. 
Author Organs Involved 
--=+ 
78 Smith & Yanagisawa Nose, ethmoid sinus, orbit, cavernous 
sinus, meninges and bra~n 
Lie-Kian-Joe et a1. 52 Brain, orbit, left internal carotid 
__ ----++-__,a:rt e :r. 
Lun roid 
26 Nose 
29 ~F~i~e~n=b~e~r~~&~R~i~s~l=e~-------;r=A=b~dominal ao~t=-------------------
80 
Smith & Burnham & Black Right and left internal carotid artery, 
16 
_ Josefiak 
superior saggital sinus, right lateral 
sinus, cavernous sinus, brain, nose, 
Sk~n~--------------------------~--
23 
t--..-...... llQ.n, Sealy, Felt~ --n--=B=rQnchus ------------------
79 Smith & Kirchner 
Muresan 67 
73 Romanul 
Nose, sinuses, orbit, right internal 
carotid artery, pituitary gland, 
meninges, brain 
~ ~s~ sinuses, orbit, internal carotid 
artery, pituitary gland, meninges, 
brain 
Nose, maxillary sinuses, maxillary 
bone a veolar ridge agd orbit 
Brain 
Brain, meninges, heart, pericardium, 
diaphragm, stomach, kidney 
l 
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Pulmonary Mucormycosis 
Pulmonary mucormycosis may occur by direct or 
hematogenous invasion of the lung~ It is felt that 
the organism' reaches the bronchi by inhnlation of 
the fungus from the air or possibly via chronic 
aspiration from infected paranasal sinuses. 43 Once 
the organism invades through the walls of the bronchi, 
they spread to involve blood vessels and lymphatics 
resulting in the pathologic picture discussed above. 
As a result, one usually finds a sequence of bron-
chitis (via mycotic spread within the bronchi), 
pulmonary infarction(from thrombus formation~ and 
a lobular pneumon,ia (inflammatory response to the 
fungus). These processes going on in the lung 
produce their characteristic clinical manifestations 
such as chest pain,. rales, pleural friction rub, 
bloody sputum, fever, and leukocytosis. The onset 
may be sudden or insidious. The clinical picture is 
often confusing because of the almost constant 
occurrence of mucormycosis in a person with some 
other primary disorder. This is undoubtedly the 
principal reason why the diaGnosis of mucormycosis 
is almost always missed antemortem in all the 
various clinical forms of the disease. 
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Gastrointestinal Infection 
According to the table .by Hutter, there have 
been 28 cases of gastrointestinal mucormycosis 
(esophagus, stomach, small intestine, colon) reported 
with' the. primary area of localization being the stomach. 
It is obvious that the fungus may reach the gastro-
intestinal tract by several ways such as: 
(l) Ingestion either from air contamination, 
chronically draining paranasal sinus, or 
infected sputum. 
(2) Hematogenous spread from other involved 
areas. 
(3) Direct invasion from adjacent structures. 
(4) Normal inhabitant of gastrointestinal 
tract. 
One of the first areas of spread after involvement of 
the intestine appears to be the liver via the portal 
blood stream. 9,20 The pathological picture has varied 
·somewhat in these cases. In some, mycotic abscesses69 
of the bowel wall have been the prominent feature while 
in others, 66 , 9rocal hemorrhagic necrosis and ulcerative 
lesions have been the characteristic finding. In one 
case the necrotic tissue formed masses which grossly 
resembled carcinoma?O Nevertheless, in all these cases 
the basic or initial pathological process was the invasion 
of gastrointestinal wall and subsequently the adjacent 
blood vessels by the fungus leading to their thrombosis 
and the infarction of tissue. 
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No characteristic clinical picture can be given.for 
mucormycosis of the gastrointestinal tract. It may 
simulate practically any pathological disorder found in 
this area. Most individuals die either as a result of 
se~ticemia and/or widespread dissemination to other 
organs, or from perforation and generalized peritonitis. 
The predisposing factors will be considered later. 
Head and Neck Structures 
Mucormycosis of this area of the body is of special 
interest since it usually presents a sufficiently dis-
tinctive clinical picture to make the diagnosis possible 
during life. Furthermore, the importance of an early 
diagnosis is of extreme importance since spread to the 
brain (cerebral mucormycosis) with death is almost 
always the inevitable result in the neglected case. Most 
of the cases of mucormycosis of the head and neck display 
a rather characteristic route that the fungus takes in 
its spread through this region. The fungus involves the 
nose and mouth either by inhalation of spore or by the 
fact that it may exist there as a saprophyte. From this 
region invasion of the body may occur by the vascular 
system, through direct penetration of local tissue with 
invasion
1
or by various natural channels of the body 
(paranasal sinuses, cribriform plate, gastrointestinal 
tract). A diagrammatic representation of the possible 
routes of spread is as follows: 
..... 
...., 
.)· 
Mucorales existing Direct penetration Involvement Spread throughvascular 
as saprophytes in and invasion of -,>adjacent - ~system ( e .q. int. carotid 
nose and mouth local tissue with blood vessels\,art.) and/or perineural 
\ destruction and lymphatics\lymphatics 
\ ~ : \ \ Involvement ) ! 
'{--->Of nose and- :, t \ 
\'oral cavity I ~ !espiratory tract \ \ i l. (Pulmonary mucqr- \ 
.J./ .....,.,. mycosis) '-..., \ 
Inhalation Via n'atural body ~ ':v 
~ cavities or meatae , GI tr~ct (GI __ ~Hematogenous 
1 t mucormycosis) - disseminat:bn 
Mucorales spores-.. · ' from emboli 
in air I I 
I t-+Cribiform ---~-!)<Tends to directly 
involve hypophysis, '.f.1 I plate 
Involvement , 
of eye!' 
cerebellum, and \ . 1 
frontal lobes ~ .v W 
''-,, Nasolacrimal 
"" :;uct ~ Parahasal sinus'S s 
· '"'-·.,.~ I l D.·i· re ct 
' /;. "'.,., / ·' 
' - ---~ .. --~ 
Orbit ( oculaz 
mucormycosis) 
- Cerebral 
Mucormycosis 
..., 
I 
I Invasion \, ~J 
Tends to·· involve 
ipsilater,a1·: frontal 
and ~empo.·r.~ lobes 
Sprea-d through vascular 
s1stemand/or perineural 
lymphatic~. 
~~.l!~me ~Q.f. Rqutes Qi; $P.:r~ad :i.n the Deveiopment of Cerebral Mucormycosis 
~---.;..... - - - - -
I 
t---1 
C11 
I 
". ~· 
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Signs and symptoms of the mycotic infection may 
manifest themselves anywhere along the course of this 
scheme. Involvement of the oral cavity, nose, paranasal 
sinuses and orbit may occur without cerebral lesion. ~. 
suefi ee:ses, adequate tx•ee:tnteflt may ettre the ·patient. When 
the infection is limited to the nose and paranasal sinuses, 
the term rhinomucormycosis is used; 78 if it fs localized 
to the eye, the infection is designated as ocular mucor-
87::;A mycosis. In the oral cavity, the organisms have been 
found to be able to produce a fungating mass on the hard 
palate which can subsequently slough and produce a large 
perforation. 33 
In involvement of the nose, there is often a uni-
lateral dark bloody nasal . discharge (occasionally bilateral) 
of'; short duration. Stuffi·ness of the nose may be present. 
Rhinoscopic examination ~haracteristically reveals gray-
black necrotic turbinates and/or septum. This discolorati,on 
of the nasal mucosa is felt to be the best clinical clue 
I~( ' 
_. to~presence of infection by these organisms but is 
often confused with dried blood. 78 Biopsy and culture 
of this area will readily confirm the diagnosis. When 
the sinuses become involved, the findings of acute 
sinusitis are commonly noted. Cloudy sinuses with fluid 
levels are seen on roentgenographic examination. Facial 
pain and headache are often felt and are typically 
localized in the various areas where sinus pain may be 
\ 
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experienced. However, this facial pan may be a manites~ 
tation ot local invasion as to the cheek. Involvement ot 
the cheek may be evident by nodule foi'mation and swelling 
or actual gangrene. 56 
Infection ot the eye (ocular mucormycosis) is commonly 
yery severe. A dull steady orbital pain is a common 
symptom. Usually o~e eye is involved. Ptosis and chemosis 
or lid may occur. Marked proptosis and ophthalmoplegia 
(internal and external) are ~requent findings. This is 
believed to be related to direct invasion of the eye and 
retrobulbor space by the fungus. They are accompanied 
by limitation or global motility and the abolishment or 
pupil reflexes. The pupil is usually dilated. Late in 
the course or the invasion or the eye, a loss or the ·co:i?neal 
reflex, papilledema, and facial weakness are commonly 
seen. 
The development ot cerebral mucormycosis is almost 
always the result or extension or the disease from other 
head and neck structures. It occasionally may be associ-
ated with a widely disseminated mucormycosis. The chart 
given by Hutter above indicates there are 'siX' cases reported 
of single involvement of the brain. However, it is still 
questionable whether this situation actually occurs. The 
primary source may not be easily found unless the patholo-
~ gist is extremely careful in his study since gross changes 
,. 
ot involved organs are not always evident. Furthermore, 
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the head and neck structures are not often thoroughly 
explored at autopsy and, hence, the most probable source 
of infection may be easily overlooked. Probably the 
most widely accepted case of solitary involvement of the 
central nervous system is an article reported by Gunson 
and Bowden. 37 However, even in this case, the nose and 
accessory air sinuses were not opened at necropsy. It 
has been recommended that routine examination of the 
paranasal sinuses should be performed in patients dying 
with diabetes mellitus in order to help evaluate the 
pathogenesis of mucormycosis. 80 The changes which occur 
in the brain are a result of the same characteristic 
pathological processes that occur in other parts of the 
body due to the fungus. Cerebral softening and necrosis 
are the end result of multiple areas of infarction which 
are produced by the invasion of cerebral blood vessels 
with formation of thrombi and emboli. Thrombosis of 
the internal carotid artery (unilateral or bilateral) 
h b b d th f . tl 52,56,79,80 well as een o serve ra er requen y. as 
as lateral sinus and cavernous sinus thrombosis. In the 
thrombus the characteris~ic organisms are usually found. 
Dystrophic calcification of the mycelia has been 
observed. 67 Invasion of the leptomeninges and lepto-
meningeal vessels is commonly found leading to the 
production of an acute meningitis. The signs of meningea 
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irritation are often localized to the involved side 
(especially the frontal area). Subarachnoid hemorrhage 
has been seen on several occasions. 4• 54 The organism 
may invade intracerebral vessels as well resulting in 
extension of the infection deeply into the brain with 
the production of a mycotic encephalitis. 54 manifested 
clinically by progressive lethargy and coma. In the 
areas of necrosis, infiltration of microglial macrophages 
and astrocytic proliferation may be found. Involvement 
of cranial nerves may also be associated with cerebral 
mucormycosis. 
Diagnosis of cerebral mucormycosis as well as 
infection by these organisms of other structures of the, 
e.-body by use of signs and symptoms along is quite difficult. 
It is their presence in a patient with a certain type of 
history that should make the diagnosis obvious. Generally 
speaking, it is only in a patient with characteristic 
predisposing factors (to be considered later) that the 
above mentioned signs and symptoms should suggest the 
possibility of mucormycosis or other fungus diseases 
rather than infections of bacterial and viral origin. 
In fact, it is felt that any of these findings (especially 
orbital infection, sinusitis, meningoencephalitis) in an 
uncontrolled diabetic should be considered to be due to 
mucormycosis until proven otherwise. 79 It demands a 
thorough examination of oral cavity, nose, paranasal sinus~s, 
" 
,. 
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and the eye and, if possible, biopsy of any suspicious area. 
Disseminated Mucormycosis 
There are not many articles in literature referring to 
the spread of the fungus into more than one of the three 
areas of the body mentioned above. The reason for this 
situation is not known. It may be that the patient dies 
before the organisms have a chance to become widespread. 
However, recalling that many of the changes in mucormycosis 
are entirely microscopic, it is quite possible that in many 
cases additional sites would have been found if more 
detailed tissue studies were performed postmortem. 
PREDISPOSING FACTORS 
Despite the ubiquitous presence of Mucoraceae, in-
fection by these organisms seems to be very uncommon. Thus, 
there has been much discussion in the literature as to what 
abnormalities may be present to permit these common sapro-
phytes to become pathogenic. The fact that the disease is 
seen only under certain conditions has extreme importance 
not only in its diagnosis and treatment but also in the 
theoretical implications that may be drawn concerning the 
mechanism of host resistance. The following charts indicates 
the various concurrent diseases and/or other possible pre-
disposing factors which were found in a survey of most of~he 
cases of mucormycosis reported in the literature. 
) 
Source of Data Date 
of 
Report 
- #= .. 
69 I P_~l t ~uf -·-·-·--- _ __II 1885 
Gregory, Go~%en 
&: Haymarker 1943 
~ 
r-~-~ ---, 
1
POSSIBLE PREDISPOSING F~---~----
Age 1\ Sex !Race Diabetes Acidosis Concurrent Disease or other 
(Yrs) i Mellitus of possible significant 
Any Kind predisposing factors 
·· ·j········- · · ·-·- -~-- · -- ··cL.... •• · ···-· ··-J a undi ce diarrhea lj ' . -··--------------
. I N I ... 
. II N 11--+- _+~---4-1- ·-·------·-
w-rrobe.bly Studies 'IHj-e.linized--rsr.ma. of 
l Inade-
1
Langerhans suggest diabetes 
··-- ; ----- ..9.Ua.t~--- -r----·-·-·-·-·--··----------······· ··--· ----····-
LeCompte ~ 
t Meissner 4 l! 1947 ll 57 M !I W 1\ + II t 1Hemochromato§_~~Qj.!':rb.9.f\l.~J3. 
Baker &: 11 11 Jl II I j! ' 
.. -Be'!lerance 3 
1 
1948 I 3 F : W + ll +-
1
1 .... ·~~~ 
li ,I 
Lloyd, S~ton, 
&: Hertig 1949 26 
ii 'I 
,, il q I. { ) F N r?M d ii Study !!Pregnancy, di abe tea ? 
1, !Diabetes ll Inade- il . 
. Wolf ... ~ .. Cohen 89 1.
1 
1949 I ~;-[ 1
1
\ M ' N r-.l. + _ I!,.l:::::blyl_________________ ~~--····. 1 
83 I ~ ' 1: · 
_ S.t.ratemeier . · 1950 32 __ ~, __l!_+ __ t____ _ ___ _y ____ .tlAQJ~!;~. l!.lcoholism 1
87 I. , " I I I 
Wadsworth 1951 10 !! M \l ·\ [Inadequate data presented to bel 
~~~ :i il 1 able to decide. There was ! 
1 
\; j~ !history of detached retina of 1! 
q lj. !1\ !year's duration-Coat's disease · 
'I \' : : I II 1: •~ J. 
. I -4------ . ~----------
Table 1 
• t\) 
...... 
I 
) 
: ~~-----~-----~-~~ -~---- -- r--- POSSIBLE PREDI~POSIN_G_F_A_C_mo-R~~-- r 
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From the data on all these cases, the relative incidence 
of the various concurr ent diseases or conditions found 
are shown in table Vll below. 
Table Vll 
~ 
- --,> 
Summary Of Predisposing Factors 
' 
Implicated In $6 Case's Of Mucormycosis 
1. 
--.:= ..... -
' I Number II ' Percent(%) Related Disease or Condition 
of 
Cases 
, I· I 
- ·- -
Diabetes mellitus 30 54.7 f 
- - - - ---
. 
Metabolic Diabetic 30 
- -
q_4. 7 
Acidosis Other Kind 4 7•5 j 
-
-- · ---~ ...... ~ 
- - --
"Lymphoma" Leukemia 8 15.0 
i--
Lymphosarcoma 1 1.8 
- -~ Multiple Myeloma 2 3.7 
-
-. """) 
Antimetabolites 7 13.2 -~ (6MP, 6CP 1 urethane) ... . 
. -Antibiotics (high i Chemotherapy .. dosage' or long_ _term) 13 
-
26.0 
--ACTH 
---
2 1- 3.7 - I~ -- 13--Corticosteroids 26.0 
(long term) ' r 
- -
Cirrhosis _ _ 1 1.8 
Liver Disease Hemachroma to srs - -- 1 1.8 
_ HeJ2a ti tis 1 1.8 
Kwashiorkor 1 1.8 --I 
·""-· 
.. 
--
•' 
Kidney Disease 5 9.4 
and uremia 
- --·'" 
Diarrhea 3 5.6 
- -
X-Ray 2 3.7 
--- - -
Pneumonia 1 1.8 
~-
Severe Thermal Burn 1 1.8 
Cholecystotomy 1 1.8 -~ 
- -
·- -
Acute Alcoholism 1 1.8 
Pregnancy 1 1.8 
--4-' I Ruptured appendix 1 1.8 
_ .. _ 
-
·- . 
Congenital Heart Disease 1 1.8 
! - -Cushing's Syndrome ~ 1 1.8 I 
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From the data in tables 1-Vl. there is no evidence 
to suggest that age. sex. or race are important etiological 
factors in themselves. 
It is readily apparent from table Vll that the 
majority of the recorded cases of mucormycosis have occurred 
in patients with diabetic acidosis. In addition, many 
cases also appear to be associated with various lymphomatous 
disorders (especially leukemia) and treatment with anti-
metabolites, steroid~ and antibiotics. However, in many 
of these cases several of these conditions were present 
at the same time and, hence it is difficult to determine 
if one is dealing with a combination of contributory 
factors or that some of them actually represent spurious 
relations. The association of hemochromatosis with the 
fungus infection is undoubtedly accidental. In my 
opinion, at the present time there is no unequivocal 
case in the literature in which a definite absence of 
predisposing factors has been shown. 
The actual mechanism whereby these disorders may 
result in increased susceptibility to mucormycosis is 
unknown. Nevertheless, the data from these cases as 
well as various experimental studies suggests certain 
possibilities. It seems apparent from the clinical data 
that acidosis in some manner may provide a favorable 
environment for the growth of the fungus. This idea is 
supported by various experimental studies. Elder and 
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Baker27 showed that intratracheal instillation of spores 
of Rhizopus arrhizus into rabbits in the acute toxic phase 
of alloxan diabetes (high blood sugar, ketosis; probably 
comparable to uncontrolled diabetes in man) resulted in 
extensive proliferation of the hyphal form of the fungus 
with invasion and death of animal with pathological 
findings closely resembling those seen in human pulmonary 
mucormycosis. However, the similar experiment repeated 
in the chronic phase of alloxan diabetes (more stable 
hyperglycemia with no ketosis; probably comparable to 
controlled disease in man) resulted in essentially no 
hyphal proliferation with only a mild pneumonia and giant 
cell reaction to the presence of the spores. Schofield 
and Baker74 found similar results in experiments performed 
on mice with alloxan-induced diabetes by intraperitoneal 
and intracerebral innoculation of spores of Rhizopus arrhizus. 
Sheldon and Bauer77 produced subcutaneous granulomas in 
rabbits by the injection of a spore suspension of Rhizopus 
oryzae. In some of the rabbits, alloxan diabetes was 
induced on the eighth, tenth, and fifteenth day after the 
injection of the spores. Activation of the infection with 
proliferation of fungus and associated invasion was noted 
only in those animals with alloxan diabetes that showed 
acetonuria. In the other animals, the spore suspension 
remained confined to the site of innoculation and after 
ten weeks no organism could be cultured. However, in 
another experiment in rabbits by Bauer, Flanagan, and 
Sheldon10 it was demonstrated that animals with infusion 
hyperglycemia innoculated with Rhizopus oryzae developed 
fungus lesions which were less agressive than rabbits 
with acute alloxan diabetes but were more frequent and 
active than those seen in the metabolically normal animals. 
This idea that fungi may grow better in an environment 
61 
of increased glucose is also substantiated by a study. 
done in humans showing that yeasts-mostly eandida albicans-
are found much more frequently in urine containing glucose. 
Furthermore, growth of Candida species in glucose contain-
ing urine at room temperature reduced the concentration 
of the sugar. Thus, these studies all suggest that the 
increased susceptibility to Rhizopus infection in the 
acute toxic phase of alloxan diabetes may be partially 
attributable to hyperglycemia per se, but that acidosis 
is the most important factor in facilitating the prolifer-
ation and invasion of the fungus. The association of 
mucormycosis in diarrhea and kidney disease with uremia 
may also be related to the concomitant metabolic acidosis 
so frequently seen in these conditions. Thus it seems 
that metabolic acidosis, diabetic or otherwise, favors the 
growth of Mucoraceae. There is evidence of other factors 
in diabetes which may increase the susceptibility to 
infection. Bauer et a1. 10 have observed degenerative 
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changes and possible loss of phagocytic ability in the 
leukocytes of rabbits with infusion hyperglycemia and 
with acute alloxan diabetes. The extreme importance of 1 , 
the leukocytes in host resistance has been shown by ) ;t( 
Rich and .McKee 7l who noted that removal of leukocytes ~vJ! . , 
eve,~--~~·~a~;~ns highly immunized to pneumococci will// 
still die from these organisms. The same authors72 
have also demonst.rated that animals lacking leukocytes 
will succumb to infection even with avirulent pneumococci. 
It has been determined that the cardinal feature of the 
metabolism of the polymorphonuclear leukocytes is its 
high aerobic lactic acid production.64 Dubos24 , 25 has 
shown inYitro that lactic acid is highly bactericidal 
whereas ketone bodies tend to render bacterial cultures 
more resistant to adverse effect of this acid. Thus, 
the ketone bodies which accumulate in vivo in uncontrolled 
diabetes and starvation may also interfere with the natural 
bactericidal effects of lactic acid. It is very possible 
that this is likewise true with respect to fungi. 
Furthermore, Martin and his associates58 have demonstrated 
that the polymorphonuclear leukocytes of diabetic patients 
have impairment of glycolytic process and produce less 
lactic adid than those from normal individuals. This 
reduction in bactericidal:.capaci ty of the leukocyte can be 
reversed by insulin. This is interesting since infections in 
diabetics are known to be associated with some degree 
-32-
of insulin resistance. 2 The role of lactic acid in host 
resistance to fungus diseases is an important field for 
further research. Loss of phagocytic ability of macro-
phages and giant cells and devitalization of tissue 
have also been sugsested as a possible cause of the 
increased susceptibility of animals with acute alloxan 
diabetes to mucormycosis. 27 Other factors mentioned in 
the decreased resistance to infection in diabetes are 
as follows: 
(1) Formation of antibodies in smaller 
amounts than in normal persons. 
(2) Lowered state of general cellular 
nutrition. 
(3) Subnormal activity of complement. 
{4) Depressed levels of properdin. 
(5) Vascular insufficiency. 
However, metabolic acidosis still seems to be the thing 
most closely associated with the susceptibility to muco~ 
mycosis. 
The important role of acidosis naturally makes one 
wonder what part the adrenals and pituitary may play·in 
this disease since it is well known that there is a 
marked ketogenic and/or diabetogenic action of some of 
the pituitary and adrenal hormones.l, 75 It is apparent 
from the data in table Vl that ACTH and steroid therapy 
is likely to represent another predisposing factor. It 
" 
. ' 
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is interesting to speculate that the reason ACTH and 
steroids are predisposing factors in mucormycosis is 
the same as in the patient with diabetes mellitus, 
namely ketosis. There is even experimental evidence 
of possibly a similar mechanism in that the treatment 
of normal leukocytes with cortisone and hydrocortisone 
produces a decrease in lactic acid production.57 The 
injection of cortisone into animals has been found to 
reduce the phagocytic activity of leukocytes and, in 
addition, decrease the production of antibodies. 65 
Other properties of steroids that have been implicated 
as possible causes in the reduction of host resistance 
are their ability to reduce blood flow due to increased 
arteriolar tone~5 to decrease llberation leukotoxin by 
damaged cells~2 and to depress,: · fibroplastic prolifer-
ation.63 With the frequent use of steroid in maligdancy 
and many other conditions, there has been an increase 
in the number of so-called "steroid diabetics".34 In 
fact, Glickman and his associates34 state that they 
have observed a patient being treated for lymphosarcoma 
with cortisone who developed a severe diabetic adidosis. 
Bauer, Wallace, and Sheldon10 found that cortisone 
administered to rabbits preceding innoculation (4-23 
days) with Rhizopus oryzae slightly decreased the 
resistance of the animal to the organism but did not 
lead to widespread infection as did acute alloxan 
. 
·n 
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diabetes. The fact that the results were not very dramatic 
may have been related to a different degree of activity 
of cortisone in rabbits as compared with man or the time 
alloted precedinG innoculation of the funfUS was of too 
short a duration. Even in man, it is well known that it 
is u~ually only after long term administration of steroids 
that one notices the harmful effects. Furthermore, there 
are many examples in the literature where.administration of 
steroids have markedly increased host susceptibility to 
fungal infections. 90 , 85181 Baker et al6 found that 
cortisone favors the dissemination of Rhizopus oryzae in 
rats, mice, and guinea pigs. The reported cases of mucor-
mycosis occurring in patients with Cushing's disease, and 
pregnancy could be easily explained by diabetoiogenic 
effects of the steroid:hormones {especially hydrocortisone). 
70,42,21 
that are produced in increased amounts in both conditions. 
Antibiotic therapy is likely to represent another 
predisposing factor, as suggested by clinical and experimental 
observations. Antibiotics have long been known to be able 
to alter and/or destroy normal bacterial flora and allow 
either resistant bacterial or fungi to multiply rapidly. 
Kligman47 postulates that this situation in a person with 
reduced bodily defense; as from serious illness, malnu-
trition, surgical traUma, or old age may permit 
"opportunistic fungi" to invade and lead to the patient's 
demise. In this concept, the increased susceptibility to 
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infection is due to change in the host rather than to 
any effect on the fungus. 
Combined antibiotic and steroid therapy is 
apparently much more dangerous than antibiotics given 
alone. In 13 cases of the fungus infection in associ-
ation with antibiotic and steroid therapy discussed by 
Torack, 85 it was noted that surface proliferation of 
fungi occur when antibiotics are siven alone whereas 
invasiveness into the tissues is associated with combined 
antibiotic and steroid therapy. 
There appears to be an association between the. use of 
various antimetabolites (e.q. 6-mercaptopurine, 6-
chlorpurine, urethane) and the development of mucormycosis. 
The use of these agents are known to be able to produce 
ulcerations of the oral cavity and gastrointestinal tract 
·15 
with diarrhea. It is possible that these ulcers serve 
as portals of entry for the fungus and/or that diarrhea 
with dehydration and metabolic acidosis further decreases 
the host's resistance to infection. Nitrogen mustard 
must also be considered as a possible predisposing factor 
since mucormycosis has been produced experimentally in 
rabbits by the induction of severe leukopenia and 
granulocytopenia with this drug.l2 
The finding of mucormycosis in patients with leukemia 
is not surprising since these patients possess a 
multiplicity of the postulated predisposing factors (altered 
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leukocyte metabolism, debilitation, prolonged treatmmt 
with ACTH, steroids and antimetabolites). However, as 
indicated earlier in this paper, it is very difficult to 
separate out the relative importance of the various 
factors in such a patient. W~ith the introduction within 
the last ten years, of the use of multiple antibiotics, 
ACTH, various steroids and antimetabolites in the 
treatment of leukemia, there has been noted a progressively 
82 increasing occurrence of fungus diseases in such patients. 
In summary, the principal factors predisposing to 
mucormycosis appear to be as follows: (1) metabolic 
acidosis and especially ketosis, (2) prolonged or excessive 
treatment with corticosteroid hormones, ACTH, antibiotics 
and antimetabolites, and (3) leukemia. As mentioned 
above, the steroids and ACTH may be producing their 
effects mainly via their ketogenic action which in turn 
may alter leukocyte metabolism. Thus, it is apparent that 
in all three instances, with the possible exception of 
antibiotics, one could explain the reduction in host 
susceptibility to mucormycosis in terms of an altered 
leukocyte metabolism. This concept may even hold true with 
respect to the antibiotics since some of the evidence 
considered earlier in this study suggests that invasiveness 
of fungi with antibiotics can occur only in a person already 
possessing a decreased resistance to infection. 
. 
' 
-
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PROGNOSIS AND TREAT~lliNT 
Mucormycosis is felt to be the most acutely fatal 
mycosis known, sometimes killing the patient in a matter 
of days. 7 Most of the articles report the duration of .. 
the disease as varying from one day to · one month. There 
are no reports of recovery from visceral mucormycosis 
before 1951. Since that time, nine cases have been 
reported in which the patient survived. These are as 
follows: 
Table Vlll 
Cases Of Recovery From Vicera:J.. Mucormycosis 
Author Type of involvement 
Harris 39 Central nervous svstem 
McCall and Strobos 60 Central nervous system 
Muresan 67 •' Central nervous svstem 
Blankenbe rQ' 13 Pulmonary 
Dillon et al. ( 1958) 23 Pulmonary (bronchus) 
Baker 5 Ethmoid sinus 
Georgiale et al. 33 Palate, left orbit, 
.... cranial nerves 
Joe 1m d Eng 45 Stomach 
Wadsworth 87 Ocular 
. 
I 
I 
~ I 
·. 
j 
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In cases with involvement of the lung,l3,23eye87 or 
stomach45cur~s were produced surgically by lobectomy, 
enucleatio~ and partial gastrectomy respectively. 
Harris39 could not be certain what caused the 
dramatic recovery of his patient with severe diabetes 
· and cerebral mucormycosis since many types of therapy 
were used in combination. This patient was treated with 
rigid control of the diabetes, potassium iodide, desensi-
tization with a vaccine made fr6m organisms cul tu.red from 
the patient, and by the advoidance of prolonged use of 
antibiotics. The patient apparently recovered under 
this regieme except for some neurological residual 
(blindness of left eye and loss of sensation of that side 
of the face) and a relatively clean palatal perforation. 
McCall and Strobos 60 treated their patient with cerebral 
mucormycosis complicating diabetic acidosis by control of 
the diabetes, potassium iodide, parenzyme .• and Mycostan. 
Althoueh the patient survived, there was also considerable 
neurologic residual. In these two casesJ there was no 
pathologic,al confirmation of involvement of the central 
nervous system by the fungus. Nevertheless, s'tnce·· the ·clinical 
picture was so similar to that observed in other cases of 
cerebral mucormycosis, it was inferred that this disease was 
present. Recently, Muresan67 has reported the first case 
of recovery from cerebral mucormycosis in which definite 
evidence of tissue invasion of the brain was established. 
n 
r 1 
" 
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The patient in this case was thought to have a brain 
tumor and, as a result, was operated upon. A cystic 
formation was excised which on microscopic examination 
revealed organisms with the typical morphology of the 
Mucorales. The post-operative course with penicillin 
treatment was uneventful. This patient has been watched 
for two and a hal~ years since the operation and appears 
to have recovered completely with no residual manifestations. 
The other interesting aspect of this case was the apparent 
lack of predisposing factors. However, I ~eel the author 
does not supply adequate clinical data '.in"his article for 
one :to'decide with any degree of assurance that no pre-
disposing factors were present. 
In the case5 with ethmoidal sinus in~ection, the 
patient recovered after his diabetes was controlled. 
Georgiale et a1. 33 report a patient with involvement of 
the palate, eye and cranial nerves who was cured by a 
therapeutic regieme consisting o~ control of the diabetes, 
iodides, antibiotics, and desensitization to the fungus. 
At the present momen~ there is no proven effective 
chemotherapeutic agent available for treatment of mucor-
mycosis. However, recent experimental studies suggest 
that Amphotericin B may be o~ value in this disease. Chick, 
Evans, and Baker found that this drug has at least a 
fungista~ effect o~ growth of ~izopus oryzae spores 
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in rabbits18 and rats. 19 Since the drug was not 
fungicidal at least under the conditions of the experi-
ments, the authors raised the question as to whether the 
spores would germinate at a subseq~ent time. Nevertheless, 
the drug would probably be of considerable help if it 
could even delay the progression of the disease since 
it may give time for one to remove or overcome any 
predisposing factors or to permit surBical resection 
of the involved area~. At the present time there has 
been no adequate trial of this drug in patients with 
mucormycosis since the disease is so seldomly diagnosed 
antemortem. 38 The importance of early recognition of 
this disease in the nasal and paranasal phase before 
the infection has spread to the brain producing 
irreversible damage of. vital tissue cannot be over-
emphasized. Time is needed to control the patient's 
disturbed metabolism and/or to revaluate his ·drug th.e'l'apy· ... 
This can only be obtained by an early diagnosis. 
SUMMAR'f 
In conclusion, I feel it is important to re-
emphasize the extreme importance that certain pre-existing 
diseases and iatrogenic factors may play in the developmemt 
of mucormycosis. In fact, it is unlikely that this fUngus 
can cause human infection without the presence of 
-41-
predisposing conditions. Early diagnosis of the disease 
before it has spread from the portal of entry to the 
brain or lungs should provide an increase in the number 
of survivors. However, most important is prophylaxis 
through more judicious use of chemotherapeutic agents 
and the strict control of acidosis under any condition, 
especially in the patient with diabetes mellitus. If 
this situation is impossible, one should always be 
alert to the possibility of a superimposed infection 
with mucormycosis as well as with other mycotic organisms. 
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